AWS launched Amazon Bio Discovery, an agentic AI platform designed to speed antibody discovery by combining a catalog of foundation models with an AI agent that selects models and evaluates candidates for lab synthesis and testing. AWS described the workflow as a lab-in-the-loop process, where results are routed back to refine subsequent rounds. The offering is intended to reduce the need for manual model orchestration and to provide enterprise-scale access for pharmaceutical, biotech, and academic teams. AWS said it will include an antibody benchmark dataset to assess attributes like manufacturability and stability, and it highlighted integrated laboratory partners to test top AI-designed candidates. AWS positioned the product as accessible to researchers without deep computational expertise, while early adopters listed include MSK, Bayer, the Broad Institute, and Fred Hutch Cancer Center. The company also stated the platform’s privacy and security approach is built for regulated R&D environments. For biotech organizations, the launch intensifies competition in AI-enabled discovery infrastructure and increases pressure on internal discovery teams and protein-design CROs to demonstrate faster iteration cycles tied to wet-lab execution.